FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901683875> ?p ?o ?g. }

• W2901683875 abstract "A multi-biomarker disease activity (MBDA) score has been validated as an objective measure of disease activity in rheumatoid arthritis (RA) and shown to track response to treatment with several disease-modifying anti-rheumatic drugs (DMARDs). The objective of this study was to evaluate the ability of the MBDA score to track response to treatment with rituximab. Data were used from 57 RA patients from three cohorts treated with rituximab 1000 mg and methylprednisolone 100 mg at days 1 and 15. The MBDA score was assessed in serum samples obtained at baseline and 6 months. Spearman’s rank correlation coefficients were calculated for baseline values, 6-month values, and change from baseline to 6 months (∆), between MBDA score and the following measures: disease activity score assessing 28 joints (DAS28) using erythrocyte sedimentation rate (ESR) or high-sensitivity C-reactive protein (hsCRP), ESR, (hs)CRP, swollen and tender joint counts assessing 28 joints (SJC28, TJC28), patient visual analogue scale for general health (VAS-GH), health assessment questionnaire (HAQ), and radiographic progression over 12 months using Sharp/van der Heijde score (SHS), as well as six bone turnover markers. Additionally, multivariable linear regression analyses were performed using these measures as dependent variable and the MBDA score as independent variable, with adjustment for relevant confounders. The association between ∆MBDA score and European League Against Rheumatism (EULAR) response at 6 months was assessed with adjustment for relevant confounders. At baseline, the median MBDA score and DAS28-ESR were 54.0 (IQR 44.3–70.0) and 6.3 (IQR 5.4–7.1), respectively. MBDA scores correlated significantly with DAS28-ESR, DAS28-hsCRP, ESR and (hs)CRP at baseline and 6 months. ∆MBDA score correlated significantly with changes in these measures. ∆MBDA score was associated with EULAR good or moderate response (adjusted OR = 0.89, 95% CI = 0.81–0.98, p = 0.02). Neither baseline MBDA score nor ΔMBDA score correlated statistically significantly with ∆SHS (n = 11) or change in bone turnover markers (n = 23), although ∆SHS ≥ 5 was observed in 5 (56%) of nine patients with high MBDA scores. We have shown, for the first time, that the MBDA score tracked disease activity in RA patients treated with rituximab and that change in MBDA score reflected the degree of treatment response." @default.
• W2901683875 created "2018-11-29" @default.
• W2901683875 creator A5001079186 @default.
• W2901683875 creator A5017043157 @default.
• W2901683875 creator A5020390013 @default.
• W2901683875 creator A5039255500 @default.
• W2901683875 creator A5040915422 @default.
• W2901683875 creator A5042123917 @default.
• W2901683875 creator A5044386973 @default.
• W2901683875 creator A5055212576 @default.
• W2901683875 creator A5080191032 @default.
• W2901683875 creator A5081323703 @default.
• W2901683875 creator A5085023012 @default.
• W2901683875 date "2018-11-20" @default.
• W2901683875 modified "2023-10-05" @default.
• W2901683875 title "The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies" @default.
• W2901683875 cites W1964095605 @default.
• W2901683875 cites W1965723104 @default.
• W2901683875 cites W1972159654 @default.
• W2901683875 cites W2010862163 @default.
• W2901683875 cites W2028129653 @default.
• W2901683875 cites W2037874703 @default.
• W2901683875 cites W2039662997 @default.
• W2901683875 cites W2049872026 @default.
• W2901683875 cites W2063236332 @default.
• W2901683875 cites W2112482146 @default.
• W2901683875 cites W2120393706 @default.
• W2901683875 cites W2121095925 @default.
• W2901683875 cites W2124428679 @default.
• W2901683875 cites W2124502604 @default.
• W2901683875 cites W2128322769 @default.
• W2901683875 cites W2137110634 @default.
• W2901683875 cites W2139209979 @default.
• W2901683875 cites W2141624058 @default.
• W2901683875 cites W2142004396 @default.
• W2901683875 cites W2148349685 @default.
• W2901683875 cites W2154544623 @default.
• W2901683875 cites W2165724007 @default.
• W2901683875 cites W2177843344 @default.
• W2901683875 cites W2217616236 @default.
• W2901683875 cites W2256563020 @default.
• W2901683875 cites W2272609970 @default.
• W2901683875 cites W2330734629 @default.
• W2901683875 cites W2514249865 @default.
• W2901683875 cites W2545273878 @default.
• W2901683875 cites W2550726844 @default.
• W2901683875 cites W2742551065 @default.
• W2901683875 cites W3084551682 @default.
• W2901683875 cites W4211111012 @default.
• W2901683875 doi "https://doi.org/10.1186/s13075-018-1750-5" @default.
• W2901683875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6245625" @default.
• W2901683875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30458871" @default.
• W2901683875 hasPublicationYear "2018" @default.
• W2901683875 type Work @default.
• W2901683875 sameAs 2901683875 @default.
• W2901683875 citedByCount "10" @default.
• W2901683875 countsByYear W29016838752019 @default.
• W2901683875 countsByYear W29016838752020 @default.
• W2901683875 countsByYear W29016838752021 @default.
• W2901683875 countsByYear W29016838752022 @default.
• W2901683875 crossrefType "journal-article" @default.
• W2901683875 hasAuthorship W2901683875A5001079186 @default.
• W2901683875 hasAuthorship W2901683875A5017043157 @default.
• W2901683875 hasAuthorship W2901683875A5020390013 @default.
• W2901683875 hasAuthorship W2901683875A5039255500 @default.
• W2901683875 hasAuthorship W2901683875A5040915422 @default.
• W2901683875 hasAuthorship W2901683875A5042123917 @default.
• W2901683875 hasAuthorship W2901683875A5044386973 @default.
• W2901683875 hasAuthorship W2901683875A5055212576 @default.
• W2901683875 hasAuthorship W2901683875A5080191032 @default.
• W2901683875 hasAuthorship W2901683875A5081323703 @default.
• W2901683875 hasAuthorship W2901683875A5085023012 @default.
• W2901683875 hasBestOaLocation W29016838751 @default.
• W2901683875 hasConcept C126322002 @default.
• W2901683875 hasConcept C185592680 @default.
• W2901683875 hasConcept C1862650 @default.
• W2901683875 hasConcept C198451711 @default.
• W2901683875 hasConcept C2777489490 @default.
• W2901683875 hasConcept C2777575956 @default.
• W2901683875 hasConcept C2778143017 @default.
• W2901683875 hasConcept C2779338263 @default.
• W2901683875 hasConcept C2780653079 @default.
• W2901683875 hasConcept C2781197716 @default.
• W2901683875 hasConcept C55493867 @default.
• W2901683875 hasConcept C67761136 @default.
• W2901683875 hasConcept C71924100 @default.
• W2901683875 hasConcept C72563966 @default.
• W2901683875 hasConcept C77350462 @default.
• W2901683875 hasConceptScore W2901683875C126322002 @default.
• W2901683875 hasConceptScore W2901683875C185592680 @default.
• W2901683875 hasConceptScore W2901683875C1862650 @default.
• W2901683875 hasConceptScore W2901683875C198451711 @default.
• W2901683875 hasConceptScore W2901683875C2777489490 @default.
• W2901683875 hasConceptScore W2901683875C2777575956 @default.
• W2901683875 hasConceptScore W2901683875C2778143017 @default.
• W2901683875 hasConceptScore W2901683875C2779338263 @default.
• W2901683875 hasConceptScore W2901683875C2780653079 @default.
• W2901683875 hasConceptScore W2901683875C2781197716 @default.
• W2901683875 hasConceptScore W2901683875C55493867 @default.
• W2901683875 hasConceptScore W2901683875C67761136 @default.

• next